Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function

Nephrology Dialysis Transplantation

Volumn 25, Issue 6, 2010, Pages 1817-1824

  Baumann, Marcus ^a   Leineweber, Kirsten ^b   Tewiele, Marion ^b   Wu, Kun ^b   Türk, Tobias R ^b   Su, Song ^b   Gössl, Mario ^c   Buck, Thomas ^b   Wilde, Benjamin ^b   Heemann, Uwe ^a   Kribben, Andreas ^b   Witzke, Oliver ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Mayo Clinic   (United States)

Author keywords

5 6 nephrectomy; BALB c mice; Glivec Gleevec; Imatinib; Remnant kidney model

Indexed keywords

IMATINIB; MALONALDEHYDE;

ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; HEART DISEASE; HEART FUNCTION; HEART MUSCLE FIBROSIS; LIPID PEROXIDATION; MALE; MESENTERY BLOOD VESSEL; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; UREMIC CARDIAC DISEASE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBROSIS; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED BALB C; NEPHRECTOMY; OXIDATIVE STRESS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; UREMIA;

EID: 77953007689     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp708     Document Type: Article

References (48)

1. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 63: S80-S83
2. Rambausek M, Amann K, Mall G et al. Structural causes of cardiac dysfunction in uremia. Ren Fail 1993; 15: 421-428
3. Stewart GA, Gansevoort RT, Mark PB et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005; 67: 217-226
4. Ponten A, Folestad EB, Pietras K et al. Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res 2005; 97: 1036-1045
5. Reigstad LJ, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 2005; 272: 5723-5741
6. Kliem V, Johnson RJ, Alpers CE et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996; 49: 666-678
7. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-193
8. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38: S28-S36
9. Zhang H, Wada J, Kanwar YS et al. Screening for genes up-regulated in 5/6 nephrectomized mouse kidney. Kidney Int 1999; 56: 549-558
10. Hong YL, Yeh SL, Chang CY et al. Total plasma malondialdehyde levels in 16 Taiwanese college students determined by various thio-barbituric acid tests and an improved high-performance liquid chro-matography-based method. Clin Biochem 2000; 33: 619-625
11. Brodde OE, Brinkmann M, Schemuth R et al. Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest 1985; 76: 1096-1101
12. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive Rats. Circ Res 1977; 41: 19-26
13. Wang D, Chabrashvili T, Borrego L et al. Angiotensin II infusion alters vascular function in mouse resistance vessels: roles of O-2 center dot(-) and endothelium. J Vasc Res 2006; 43: 109-119
14. Leineweber K, Böse D, Vogelsang M et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. Circulation 2006; 47: 981-986
15. Amann K, Tornig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301
16. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003; 64: 350-355
17. Kohler R, Eichler I, Schonfelder H et al. Impaired EDHF-mediated vasodilation and function of endothelial Ca2+-activated K+ channels in uremic rats. Kidney Int 2005; 67: 2280-2287
18. Benchetrit S, Green J, Katz D et al. Early endothelial dysfunction following renal mass reduction in rats. Eur J Clin Invest 2003; 33: 26-33
19. Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20: 933-939
20. del Carmen Medina L, Vazquez-Prado J, Garcia-Sainz JA. Cross-talk between receptors with intrinsic tyrosine kinase activity and alpha1b-adrenoceptors. Biochem J 2000; 350: 413-419
21. Chen JH, Ozanne SE, Hales CN. Analysis of expression of growth factor receptors in replicatively and oxidatively senescent human fi-broblasts. FEBS Lett 2005; 579: 6388-6394
22. Schellings MW, Baumann M, van Leeuwen RE et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006; 47: 467-474
23. del Carmen Medina L, Vázquez-Prado J, García-Sáinz JA. Cross-talk between receptors with intrinsic tyrosine kinase activity and alpha1b-adrenoceptors 2000; 350: 413-419
24. Cox ME, Ely CM, Catling AD et al. Tyrosine kinases are required for catecholamine secretion and mitogen-activated protein kinase activation in bovine adrenal chromaffin cells. J Neurochem 1996; 66: 1103-1112
25. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. AJP-Cell Physiology 2007; 292: C82-C97
26. Brenner BM. Nephron adaptation to renal injury or ablation. AJP-Re-nal Physiology 1985; 249: 324-337
27. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844
28. Wight JP, Bassett AH, Hutchesson A et al. Effect of antihypertensive therapy in experimental chronic renal failure. Miner Electrolyte Me-tab 1991; 17: 362-368
29. Suzuki H, Schaefer L, Ling H et al. Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995; 15: 129-136
30. Amann K, Tyralla K, Gross ML et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 2003; 63: 1708-1713
31. Wu TH, Hsieh SC, Li KJ et al. Altered glycosylation of Tamm-Horsfall glycoprotein derived from renal allograft recipients leads to changes in its biological function. Transpl Immunol 2008; 18: 237-245
32. Hoyer JR. Tubulointerstitial immune complex nephritis in rats immunized with Tamm-Horsfall protein. Kidney Int 1980; 17: 284-292
33. Mayrer AR, Kashgarian M, Ruddle NH et al. Tubulointerstitial nephritis and immunologic responses to Tamm-Horsfall protein in rabbits challenged with homologous urine or Tamm-Horsfall protein. J Immunol 1982; 128: 2634-2642
34. Turner JJ, Stacey JM, Harding B et al. UROMODULIN mutations cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol Metab 2003; 88: 1398-1401
35. Hart TC, Gorry MC, Hart PS et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39: 882-892
36. Lynn KL, Marshall RD. Excretion of Tamm-Horsfall glycoprotein in renal disease. Clin Nephrol 1984; 22: 253-257
37. Thornley C, Dawnay A, Cattell WR. Human Tamm-Horsfall glyco-protein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci (Lond) 1985; 68: 529-535
38. Chakraborty J, Below AA, Solaiman D. Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 2004; 32: 79-83
39. Torffvit O, Kamper AL, Strandgaard S. Tamm-Horsfall protein in urine after uninephrectomy/transplantation in kidney donors and their recipients. Scand J Urol Nephrol 1997; 31: 555-559
40. Torffvit O, Jorgensen PE, Kamper AL et al. Urinary excretion of Tamm-Horsfall protein and epidermal growth factor in chronic ne-phropathy. Nephron 1998; 79: 167-172
41. Sejdiu I, Torffvit O. Decreased urinary concentration of Tamm-Hors-fall protein is associated with development of renal failure and cardiovascular death within 20years in type 1 but not in type 2 diabetic patients. Scand J Urol Nephrol 2008; 42: 168-174
42. Bleyer AJ, Hart TC, Shihabi Z et al. Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. Kidney Int 2004; 66: 974-977
43. Rampoldi L, Caridi G, Santon D et al. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 2003; 12: 3369-3384
44. Lhotta K, Gehringer A, Jennings P et al. Familial juvenile hyperuri-cemic nephropathy: report on a new mutation and a pregnancy. Clin Nephrol 2009; 71: 80-83
45. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
46. Tamm I, Horsfall F. Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Med 1950; 74: 108-114
47. Wu TH, Hsieh SC, Yu CY et al. Intact protein core structure is essential for protein-binding, mononuclear cell proliferating, and neutrophil phagocytosis-enhancing activities of normal human urinary Tamm-Horsfall glycoprotein. Int Immunopharmacol 2008; 8: 90-99
48. Ross BD, Guder WG. Heterogeneity and Compartmentation in the Kidney. Metabolic Compartmentation. (London) Ltd.: Academic Press Inc., 1982; 1st edn: 363-409